1Falagas ME,Bliziotis IA,Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies[J]. Crit Care, 2006,10 : R48.
2Falagas ME, Kasiakou SK. Colistin.. the revival of polymyxins for the management of multidrug resistant Gram-negative bacterial infections[J]. Clin Infect Dis, 2005,40 : 1333-1341.
3Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan [J]. Emerg Infect Dis, 2002,8 : 827-832.
4Davis KA, Moran KA, McAllister CK, et al. Multidrug-resist ant Acinetobacter extremity infections in soldiers[J]. Emerg Infect Dis,2005,11 : 1218 -1224.
5Kang M, Xie Y, Mintao C, et al. Antimicrobial susceptibility of clinical isolates from earthquake victims in Wenchan[J]. Clin Microbiol Infect, 2009,15 : 87-92.
6Gales AC,Jones RN,Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical iso lates of Gram-negative bacilli: report from the SENTRY anti microbial surveillance programme (2001-2004)[J]. Clin Mi crobiol Infect, 2006,12 : 315-321.
7Wang H, Guo P, Sun HL. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp from Chinese hospitals[J]. Antimicrob Agents Chemother, 2007,51: 4022 4028.
8Katragkou A, Roilides E. Successful treatment of multidrug resist ant Acinetobacter baumannii central nervous system infections with colistin[J]. J Clin Microbiol, 2005,43 :4916 -4917.
9Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence[J]. Int J Antimicrob Agents, 2007,29 : 9-25.
10Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglyeosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multi-resistant Acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2002,46: 1946-1952.
